Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 25, 2012

Phase III Success for Oral Testosterone Replacement Therapy

  • Clarus Therapeutics reported positive topline data from a Phase III trial evaluating its oral testosterone replacement therapy CLR-610 in men with low serum testosterone. Results from the positive-controlled trial showed that 87% of 141 men treated with the drug achieved serum testosterone levels in the normal range (300–1,000 ng/dL) after 90 days of treatment. The average testosterone level achieved was 624 ng/dL.

    In comparison, 80% of 146 men treated with the transdermal T-gel testosterone replacement therapy achieved normal serum testosterone levels, which averaged at 480 ng/dL. To meet FDA efficacy guidelines for a testosterone replacement therapy 75% of treated men should achieve testosterone levels in the normal range after 90 days of therapy.

    “We are particularly excited about the significant number of men receiving CLR-610 who achieved normal testosterone levels in this study,” comments Bela S Denes, M.D., Clarus CMO. “Market research shows that men currently being treated for low T with transdermal or injectable products would overwhelmingly prefer an oral option. Thus, we believe CLR-610 will have strong appeal.”

    CLR-610 is Clarus Therapeutics' primary development candidate. The testosterone undecanoate prodrug has been formulated to facilitate absorption via the intestinal lymphatic pathway, and is taken orally twice a day as a softgel capsule.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »